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Indexed Left Atrial Volume Is Superior to Left Atrial
Diameter in Predicting Nonvalvular Atrial Fibrillation
Recurrence after Successful Cardioversion:
A Prospective Study
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Background: Although indexed left atrial volume (iLAV) is the most accurate measure of left atrial size, it
has not been evaluated prospectively as predictor of recurrence of atrial fibrillation (AFib) after successful
cardioversion (CV). Methods: We prospectively selected 76 patients (mean age 66.1± 13.6 years, 65.8%
men) with AFib who underwent successful CV. Baseline clinical and echocardiographic characteristics
were obtained before CV. LAV was measured using Simpson’s method and indexed to body surface
area. All patients were scheduled for follow-up visit at 1, 6, 12 months, and then annually. A 24-hour
Holter ECG was performed within 6 months and each time the patients reported symptoms suggestive
of arrhythmia. Results: The 52 patients (68.4%) with AFib recurrence had larger iLAV (35.5 ± 8.9 mL/m2
vs 27.0 ± 6.7 mL/m2, P < 0.001). Anteroposterior LA diameter was not associated with AFib relapse (OR
1.08, 95% CI: 0.96–1.21, P = 0.09). Each unit increase in iLAV was associated with a 1.15-fold increased
risk of recurrence (OR 1.15, 95% CI: 1.06–1.25, P < 0.001). In a multivariable model, iLAV remained the
only independent predictor of relapse (adjusted OR 1.14, 95% CI: 1.02–1.28, P = 0.02). The area under
ROC curves, generated to compare LA diameter, and iLAV as predictors of AFib recurrence were 0.56
(SE 0.07) versus 0.78 (SE 0.05), respectively (P = 0.003). Conclusion: This is the first prospective study
to show that larger iLAV, as a more accurate measure of LA remodeling than anteroposterior diameter, is
strongly and independently associated with a higher risk of AFib recurrence after CV. (Echocardiography
2012;29:276-284)
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Despite the use of potent antiarrhythmic drugs
(AAds), atrial fibrillation (AFib) relapse after car-
dioversion (CV) remains common,1 leading to
serial CV strategy. Among AFib recurrence pre-
dictors,2–4 M-mode anteroposterior left atrial di-
ameter (AP-LAd), a unidimensional measure of
left atrial (LA) size, was shown to be incremen-
tal to clinical risk factors.2,5,6 Although this mea-
surement has been widely used in clinical prac-
tice and research, it inaccurately represents true
LA size.7,8 LA volume (LAV) determination is pre-
ferred because it allows a more accurate assess-
ment of the asymmetric remodeling of the LA and
it is a stronger predictor of cardiovascular out-
comes than linear LA dimension.7 Nevertheless,
its role in predicting recurrence of AFib after suc-
cessful CV has been recently examined for the first
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time by our group in a retrospective study.9 Only
one study has evaluated indexed left atrial vol-
ume (iLAV) as predictor of AFib, but the patients
were maintained in sinus rhythm successfully for
at least 1month after conversion and then studied
by transthoracic and transesophageal echocar-
diography.10 Therefore, the aims of the present
work are to investigate in a prospective study
whether iLAV predicts AFib recurrence after suc-
cessful CV (pharmacological or direct-current)
or it is incremental to clinical risk factors and
AP-LAd.
Methods:
Study Population:
Given the pilot scope of the work, no formal sam-
ple size computation was performed. Nonethe-
less, before patient enrolment, we expected that
including a total of 76 patients would have lead
to 95% confidence intervals for AFib recurrence
ranging between 50% and 72%, in keeping with
our previous retrospective work9 on this topic
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showing a point estimate of 61%. We prospec-
tively enrolled patients referred to emergency
room for AFib, who underwent successful phar-
macological or direct current CV between January
2008 and January 2009. Exclusion criteria were
history of other atrial arrhythmias, congenital
heart disease, moderate to severe valvular heart
disease (including mitral valve prolapse), thyroid
dysfunction, chronic obstructive pulmonary dis-
ease, acute (within 1 month before and at any
time after CV) or chronic inflammatory disease,
any time cardiac surgery. Because surgical treat-
ment may represent itself a trigger for AFib and
because the mechanism underlying postopera-
tive AFib are different from other types of AFib,11
we excluded patients who underwent all types
of surgery within 3 months before and at any
time after CV. We also excluded patients who re-
ceived permanent pacemaker at any time before
or after the date of the CV. We included patients
who had successful restoration of sinus rhythm
after CV and who had a transthoracic echocar-
diographic examination just before the CV. Each
patient gave written informed consent and the
study protocol was approved by our Institution
Ethic Committee.
Clinical Data:
All clinical data on AFib risk factors were ob-
tained at the time of the echocardiogram be-
fore CV and these included age, sex, hyperten-
sion, diabetes mellitus, hyperlipidemia, smoking,
family history of cardiovascular disease, medical
history of cardiovascular disease, duration of the
AFib before CV, noting if it was of unknown
duration, and number of previous episode(s) of
AFib, noting if symptomatic for congestive heart
failure. Hypertension, diabetes mellitus, hyper-
lipidemia, smoking, family history of cardiovas-
cular disease,12 and CHA2DS2VASc13 were de-
fined according to the latest guidelines. The Old
CHADS2 [cardiac failure, hypertension, age, dia-
betes, stroke (doubled)] risk index is based on a
point system in which two points are assigned
for a history of stroke or TIA and one point each
is assigned for age >75 years, a history of hy-
pertension, diabetes, or recent cardiac failure; in
patients with a CHADS2 score≥2, chronic oral an-
ticoagulation therapy is recommended. The new
CHA2DS2-VASc [congestive heart failure, hyper-
tension, age ≥75 (doubled), diabetes, stroke
(doubled), vascular disease, age 65–74, and sex
category (female)] extends the CHADS2 scheme
by considering additional stroke risk factors al-
lowing a better risk stratification. This scheme is
based on a point system in which two points are
assigned for a history of stroke or TIA, or age
≥75; and one point each is assigned for age 65–
74 years, a history of hypertension, diabetes, re-
cent cardiac failure, vascular disease (myocardial
infarction, complex aortic plaque, and PAD, in-
cluding prior revascularization, amputation due
to PAD, or angiographic evidence of PAD, etc.),
and female sex. Chronic oral anticoagulation ther-
apy is recommended for a score ≥ 2.
The type of CV and the AAD used for phar-
macological CV were recorded. All direct-current
CVs were performed using biphasic defibrilla-
tor. Pharmacological therapy after CV, including
AADs and the so-called “upstream therapy” for
AFib recurrence prevention which encompasses
ACE-inhibitors, Angiotensin II receptors blockers,
statins, and polyunsaturated fatty acids, was also
noted. Data collections and LA size assessment
were performed in a blinded fashion.
Echocardiographic Data:
LAV was assessed off line with Simpson’s method
using apical four-chamber and apical two-
chamber views at ventricular end-systole8 and in-
dexed to body surface area calculated using the
DuBois and DuBois formula.14 Left atrial diam-
eter was measured using two-dimensional (2D)
anteroposterior linear dimension obtained from
the parasternal long-axis view. Interoperator vari-
ability of our laboratory in assessing LA size has
been previously published.15 For AP-LAd assess-
ment, the mean difference ± standard devia-
tion between the measurements was 0.2 ± 2.0
mm and interclass correlation coefficient was
99.1%; for LAV interobserver mean, difference
was 0.2 ± 5.5 mL and interclass correlation co-
efficient was 98.4%, both indicating outstanding
reliability. Patients with suboptimal images that
precluded the assessment of LA volume were ex-
cluded. Left ventricular volume has been evalu-
ated by the biplane method of disks (modified
Simpson’s rule)16 and then indexed to BSA. Left
ventricular (LV) ejection fraction was visually es-
timated, a quick and widely used method that
was documented to have an accuracy compara-
ble to the other methods in assessing LV ejec-
tion fraction.17 Accordingly, we have compared
the result of the EF measured with the volumes
formula [(End systolic – End diastolic)/End sys-
tolic] with the visually estimated ones and the
results are definitively analogous 60.8 ± 5.2 vs
62.1 ± 6.1. We did not used neither Teichholz
nor Quinones methods of calculating EF from LV
linear dimensions because they may result in in-
accuracies as a result of the geometric assump-
tions required to convert a linear measurement
to a three-dimensional volume. Left ventricular
mass was calculated according to the current rec-
ommendations for chamber quantification,8 and
indexed to body surface area (iLV-mass). Valvular
regurgitation was assessed semiquantitatively by
using color Doppler as absent, mild, moderate, or
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severe; alvular stenosis was assessed by Doppler
analysis with the established methods.18,19 All
other echocardiographic data were obtained ac-
cording to the American Society of Echocardiog-
raphy standards.8
Outcomes Ascertainment:
After CV, all patients were scheduled for follow-up
visit, including 12-lead ECG at 1, 6, 12 months,
and then annually. At least one 24-hour Holter
ECG was performed within 6 months, and also
each time the patients reported symptoms sug-
gestive of arrhythmia.
To define AFib recurrence confirmation by
ECG was required. No distinction was made be-
tween paroxysmal and persistent AFib relapse. Pa-
tients with a scheduled follow-up of at least 6
month were included.
Statistical Analysis:
Results are presented as mean ± SD for contin-
uous variables and as frequency (percentages)
for categorical variables. Group comparisons were
performed using the t-test or chi-square test, as
appropriate. Logistic regression analysis was used
to identify the univariate andmultivariable predic-
tors of AFib recurrence, the odds ratio (OR) and
95% confidence interval (CI) are shown. Pearson
correlation was used to measure the association
between two quantitative variables. Receiver–
operator characteristic (ROC) curves were gen-
erated to compare M-mode AP-Lad, and iLAV as
predictors of recurrence of AFib after CV. The ar-
eas under the ROC curves were compared using
the method of DeLong et al.20 All tests are two
sided and P < 0.05 was considered to be sig-
nificant. Statistical analysis was conducted using
SPSS 15.0 and Medcalc 7.3.
Results:
Baseline Characteristics and Clinical
Predictors of AFib Recurrence:
We evaluate 102 consecutive patients who under-
went successful CV for AFib. After review of the
medical records, 26 patients were not included
because of the exclusion criteria. The remaining
76 patients (mean age 66.2 ± 13.6 years, 65.8%
male) represent the study population.
Termination of the arrhythmia was achieved
with pharmacological CV 40 (52.6%) and with
direct-current CV in 36 (47.4%) patients. Phar-
macological CV was obtained with 1c class AAds
34 (85.0%) and amiodarone 6 (15%).
For the overall cohort, 52 patients (68.4%) de-
veloped AFib recurrence after a median time of
4.0 (minimum to maximum: 1.0–26.3) months.
The remaining 24 (31.6%) patients were free
from AFib relapse for a median follow-up time
of 32.9 (minimum to maximum: 25.8–36.8)
months.
The baseline clinical characteristics of patients,
stratified by AFib recurrence status at follow-
up, are presented in Table I. Patients who sub-
sequently developed AFib relapse were more
likely to have hypertension, more previous AFib
episodes, and higher CHA2DS2VASc score. Each
point increase in CHA2DS2VASc score was associ-
ated with a 94% increased risk of AFib recurrence
(OR 1.94, CI: 1.17–3.22, P = 0.004).
Echocardiographic Predictors of AFib
Recurrence:
Patients with AFib recurrence had significantly
greater iLAV than patients without AFib recur-
rence (35.5 ± 8.9 vs 27.0 ± 6.7, P < 0.001,
Table II). Furthermore, they had higher iLV-mass.
Each mL/m2 increase in iLAV was associated with
a 15% increased risk of AFib relapse (OR 1.15, CI:
1.06–1.25, P< 0.001, Table III). iLAV resulted also
significantly correlated to CHA2DS2VASc score
(r = 0.45, r2 = 0.16, P < 0.001; Fig. 1). Patients
with moderate to severe LA enlargement (iLAV
more than 33 mL/m2) plus CHA2DS2VASc score
more than 2, resulted with a 9.42-fold increased
risk of AFib recurrence (OR 9.42, CI: 2.01–44.28,
P = 0.01, Table III). AP-LAd was not significantly
higher in patients with AFib relapse (Table II).
Multivariable Predictors of AFib Recurrence:
In a multivariable logistic regression model, iLAV
remained the only predictor of AFib recurrence
after adjusting for CHA2DS2VASc score, hyper-
tension, ACE-I therapy, number of previous AFib
episodes, and iLV-mass (Table IV). EachmL/m2 in-
crease in iLAV was independently associated with
a 13% increase in risk of AFib relapse (adjusted
OR 1.14, CI: 1.02–1.28, P = 0.02).
Receiver-Operator Characteristic Curves
Analysis:
ROCs were generated to compare M-mode AP-
Lad, and iLAV as predictors of recurrence of AFib
after CV (Fig. 2). The area under the curve was
0.78 ± 0.05 for iLAV versus 0.56 ± 0.07 for AP-
LAd (P < 0.003). The best discriminating value
of iLAV to predict AFib relapse was 31 mL/m2,
which had 71.2% sensitivity and 78.3% speci-
ficity. The cutoff value for severe iLAV enlarge-
ment (40 mL/m2) corresponded to 26.9% sensi-
tivity and 95.7% specificity. iLAV 42 mL/m2 was
100% specific as predictor of AFib recurrence, al-
though the sensitivity decreased to 17.3%.
Discussion:
The present is the first prospective study to show
that iLAV measured before CV is a significant and
independent predictor of AFib recurrence. It is
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TABLE I
Characteristics of the Study Population at Baseline
NO AFib Recurrence AFib Recurrence
Variable n = 24 (31.6%) n = 52 (68.4%) P
Clinical Characteristics
Sex (male) 17 (70.8) 33 (63.4) 0.52
Age (years) 63.3 ± 18.0 67.6 ± 11.0 0.20
BMI (kg/m2) 26.1 ± 2.4 27.2 ± 4.6 0.28
BSA (m2) 1.9 ± 0.2 1.9 ± 0.2 0.93
Family history of CAD 7 (29.1) 19 (36.5) 0.53
Hypertension 13 (54.2) 41 (78.8) 0.03
Dyslipidemia 8 (33.3) 25 (48.1) 0.23
Smoke 2 (8.3) 5 (9.6) 0.86
Diabetes 0 (0.0) 6 (11.5) 0.08
Known CAD 1 (4.2) 8 (15.4) 0.16
Vascular disease 0 (0) 0 (0) –
Stroke 0 (0.0) 3 (5.8) 0.23
CHA2DS2VASc 1.5 ± 0.9 2.2 ± 1.1 0.04
AFib symptomatic for CHF 0 (0.0) 1 (1.9) 0.49
AFib duration (days) 12.4 ± 3.2 27.1 ± 10.8 0.20
Unknown AFib duration 4 (16.7) 16 (30.8) 0.19
N◦ of previous AFib episodes 0.92 ± 1.4 2.40 ± 4.4 0.03
Antiarrhythmic drugs and “upstream” therapy after
cardioversion
ACE-i 2 (8.3) 17 (32.7) 0.02
ARBs 4 (16.7) 17 (32.7) 0.15
Diuretics 2 (8.3) 9 (17.3) 0.30
Dihydropyridine Ca2+ channel blockers 1 (4.2) 6 (11.5) 0.30
Verapamil 0 (0.0) 1 (1.9) 0.49
Diltiazem 0 (0.0) 0 (0.0) –
Digitalis 1 (4.2) 0 (0.0) 0.14
Beta-blockers 11 (45.8) 23 (44.2) 0.90
Ic/III class AAds 9 (37.5) 29 (55.7) 0.14
Statins 3 (12.5) 9 (17.3) 0.59
PUFA 0 (0.0) 0 (0.0) –
Values in bold are statistically significant P < 0.05.
Data are presented as mean ± SD or number (%). AFib = atrial fibrillation; CAD = coronary artery disease; CHF = congestive
heart failure; CV = cardioversion; ACE-i = angiotensin converting enzyme inhibitors; ARBs = Angiotensin II receptor blockers;
AADs = antiarrhythmic drugs; PUFA = polyunsaturated fatty acid; OR = odds ratio; CI = confidence interval.
incremental to clinical risk factors and M-mode
AP-LAd. Despite the emerging evidence that iLAV
is a better predictor of a first episode of AFib than
AP-LAd,21–23 the few studies evaluating the de-
terminants of AFib recurrence after CV focused
on AP-LAd.2,24,25 The role of iLAV in predicting re-
lapse of AFib after successful CV has been recently
examined for the first time by our group in a ret-
rospective study.9 We demonstrated that larger
iLAV before CV, as a more accurate measure of LA
remodeling than LA diameter, was strongly and
independently associated with higher risks of AFib
recurrence. Only one study has evaluated iLAV as
predictor of AFib, but the patients were main-
tained in sinus rhythm successfully for at least
1 month after conversion and then studied by
transthoracic and transesophageal echocardiog-
raphy.10 For optimal use of echocardiographic
LA size in AFib risk stratification, the method
used for accurate quantification is pivotal.26 Our
group previously demonstrated that the assess-
ment of LA size by iLAV allows identification of
patients with enlarged atria that would have been
missed if classified by AP-LAd.15 Measurement of
AP linear LA dimension by M-mode echocardio-
graphy is easy and rapid, but not reliably accu-
rate, given that the LA is not spherically shaped.
The expansion of the LA in the AP dimension
may be constrained by the thoracic cavity be-
tween the sternum and the spine. Predominant
enlargement in the superior–inferior and medial–
lateral dimensions alters LA geometry such that
the AP dimension may not be representative of LA
size. Conversely, biplane iLAV by two-dimensional
echocardiography provides a more accurate
and reproducible estimation of LA size, when
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TABLE II
Baseline Echocardiographic Characteristics of the Study
Population
No AFib AFib
Recurrence Recurrence
n = 24 n = 52
Variable (31.6%) (68.4%) P
EF (%) 62.6 ± 5.3 61.9 ± 7.5 0.67
LV-Dd (mm) 45.3 ± 6.0 46.2 ± 6.1 0.61
LV-Sd (mm) 18.1 ± 2.7 19.4 ± 4.9 0.30
AP-LAD (mm) 36.3 ± 3.2 38.1 ± 5.6 0.09
iLAV (mL/m2) 27.0 ± 6.7 35.5 ± 8.9 <0.001
iLV-mass (g/m2) 101.0 ± 26.4 120.7 ± 31.3 0.02
iLV-volume
(mL/m2)
56.13 ± 21.3 53.6 ± 17.2 0.68
Mitral
regurgitation (◦)
8 (33.3) 21 (40.4) 0.92
Aortic
regurgitation (◦)
4 (16.7) 19 (36.5) 0.19
Tricuspid
regurgitation (◦)
10 (41.7) 19 (36.5) 0.26
iLAV > 33 mL/m2 2 (8.3) 24 (46.1) 0.01
+ CHA2DS2 VASc > 2
Values in bold are statistically significant P < 0.05.
Data are presented as mean ± SD or number (%). AFib = atrial
fibrillation; EF = ejection fraction; LV-Dd = left ventricular di-
astolic diameter; AP-LAd = M-mode anteroposterior left atrial
diameter; iLAV = indexed left atrial volume; iLV = indexed left
ventricular.
compared with reference standards such as mag-
netic resonance imaging27 and three-dimensional
echocardiography.28 Accordingly, the ASE/ESC
have recommended quantification of LA size by
biplane volumetric 2D echocardiography using
either the Simpson method or the area–length
method which are comparable in accuracy and
reproducibility.8
Despite this growing evidence, the latest
guidelines for AFib management13 have included
LA size assessment just in terms of M-mode AP
dimension. The present study, confirming the re-
sults of our retrospective one, supports the find-
ings that iLAV is superior to AP-LAd as predictor
of AFib recurrence.
LA Remodeling as Predictor of AFib
Recurrence:
LA remodeling refers to a time-dependent adap-
tive regulation of cardiac myocytes in order
to maintain homeostasis against external “stres-
sors.”29 The type, extent, and reversibility of atrial
remodeling depend on the strength and the du-
ration of exposure to the stressors. The most
common stressors of atrial myocytes include vol-
ume/pressure overload and tachycardia. They are
not mutually exclusive and usually may coexist
at various times in the same patient. Increased
volume/pressure overload leads to chamber di-
latation and stretch of the atrial myocardium pro-
viding the substrate for AFib to be sustained.29
Tachycardia-induced LA remodeling is mostly re-
versible, even if a prolonged high rates of cell
depolarization makes restoring and maintaining
sinus rhythm less likely.30,31
The structural changes of the LA reflect an
average effect of left ventricle filling pressures
over time due to reduced left ventricle compli-
ance, rather than an instantaneous measurement
at the time of study.26 This is common in var-
ious conditions such as hypertension, diabetes,
coronary artery disease, and chronic heart fail-
ure,32 supporting the hypothesis that AFib may
be a symptom of an underlying left ventricle
disease. According to these findings,29 present
study shows that CHA2DS2VASc score, hyperten-
sion, and iLV-mass are associated with higher
probability of AFib relapse. Present work is the
first to evaluate the relationship between the
CHA2DS2VASc score, iLAV, and AFib recurrence
after CV. CHA2DS2VASc is the new score used
to predict the risk of stroke in AFib patients.13
We showed that it is associated with higher
risk of AFib recurrence, accordingly with the as-
sumption that the more the AFib burden the
more the risk of stroke.33 Previous studies have
demonstrated the relationship between LA di-
ameter, CHADS2, and risk of stroke.34,35 In our
study, CHA2DS2VASc score resulted also signifi-
cantly correlated to iLAV (Fig. 1). Probably the
reason is because the CHA2DS2VASc score in-
cludes the above-mentioned “stressors” leading
to LA remodeling. However, in the multivariable
model, iLAV remained the only significant predic-
tor of AFib recurrence, resulting superior to clin-
ical risk factors included in CHA2DS2VASc score,
and AADs, maybe because LA remodeling repre-
sents the final and macroscopic result of the sum
of each single clinical predictor. Otherwise, it is in-
teresting to note that patients with CHA2DS2VASc
score more than two points and moderate
to severe LA enlargement (iLAV more than
33 mL/m2) had a 9.42-fold increased risk of AFib
relapse.
It would be hard and intriguing to establish
which one is the point of no return. The risk
of AFib recurrence increases significantly for iLAV
above 31.0 mL/m2. This is quite the same value
reported by previous studies that have evaluated
the role of iLAV as predictor of major cardiovascu-
lar events and mortality26 and by our retrospec-
tive experience.9 It is likely that some grade of ir-
reversibility begins in the range of moderate iLAV
enlargement. As expected, the larger the iLAV,
the more is the risk of AFib relapse, probably be-
cause of the higher grade of LA fibrosis.
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TABLE III
Univariate Model
Variable P OR CI
Clinical Characteristics
Sex (male) 0.52 0.71 0.25–2.03
Age (years) 0.20 1.02 0.99–1.05
BMI (kg/m2) 0.28 1.08 0.94–1.23
BSA (m2) 0.93 1.11 0.08–14.90
Family history of CAD 0.53 1.40 0.49–3.98
Hypertension 0.03 3.15 1.11–8.95
Dyslipidemia 0.23 1.85 0.67–5.07
Smoke 0.86 1.17 0.21–6.51
Diabetes 0.08 0.66 0.55–0.78
Known CAD 0.16 4.18 0.49–35.51
Stroke 0.23 0.67 0.57–0.79
CHA2DS2VASc 0.04 1.94 1.17–3.22
Afib symptomatic for CHF 0.49 0.68 0.58–0.79
Afib duration (days) 0.20 1.01 0.98–1.03
Unknown Afib duration 0.19 2.22 0.65–7.56
N◦ of previous Afib episodes 0.03 1.20 1.01–1.54
Echocardiography Data
EF (%) 0.67 0.98 0.91–1.07
LV-Dd (mm) 0.61 1.02 0.93–1.13
LV-Sd (mm) 0.30 1.09 0.92–1.30
AP-LAD(mm) 0.09 1.08 0.96–1.21
iLAV (mL/m2) <0.001 1.15 1.06–1.25
iLV-mass (g/m2) 0.02 1.03 1.002–1.05
iLV-volume (mL/m2) 0.68 1.00 0.96.1.03
Mitral regurgitation (◦) 0.92 0.94 0.31–2.88
Aortic regurgitation (◦) 0.19 2.29 0.64–8.10
Tricuspid regurgitation (◦) 0.26 0.49 0.16–1.52
iLAV > 33 mL/m2 + CHA2DS2VASc > 2 0.01 9.42 2.01–44.28
Antiarrhythmic Drugs and “Upstream” Therapy after Cardioversion
ACE-i 0.02 5.34 1.12–25.40
ARBs 0.15 2.43 0.71–8.22
Diuretics 0.30 2.30 0.46–11.59
Dihydropyridine Ca2+ channel blockers 0.30 3.00 0.34–26.42
Verapamil 0.49 0.68 0.58–0.79
Digitalis 0.14 0.31 0.22–0.43
Beta-blockers 0.90 0.93 0.35–2.47
Ic/III class AAds 0.14 2.10 0.78–5.66
Statins 0.59 1.46 0.36–5.98
Values in bold are statistically significant P < 0.05.
AFib= atrial fibrillation; CAD= coronary artery disease; CHF= congestive heart failure; CV= cardioversion; LV-Dd= left ventricular
diastolic diameter; AP-LAd = M-mode anteroposterior left atrial diameter; iLAV = indexed left atrial volume; iLV = indexed left
ventricular; ACE-i = angiotensin converting enzyme inhibitors; ARBs = Angiotensin II receptor blockers; AADs = antiarrhythmic
drugs; PUFA = polyunsaturated fatty acid; OR = odds ratio; CI = confidence interval.
Strengths and Limitations:
The major strength of the present study is that
it is the first to test prospectively the predic-
tive role of LAV in the post CV setting. Fur-
thermore, all echocardiographic studies were
performed before CV according to the Ameri-
can Society/European Society of Echocardiogra-
phy standards and interoperator variability of our
laboratory in assessing LAV has been previously
published.15 LAV was indexed to body surface
area. Physicians measuring iLAV data off line were
blinded to the clinical data and outcomes of the
patients.
The clinical follow-up was scheduled at 1,
6, and 12 months and then annually; at least
one 24-hour Holter ECG was performed within
6 months, and also each time the patients re-
ported symptoms suggestive an arrhythmia. Fur-
thermore, we excluded patients with a follow-
up of less than 6 months in order to guarantee
a sufficiently long follow-up. Only clinically doc-
umented AFib was considered, thus we cannot
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Figure 1. Pearson correlation between iLAV and
CHA2DS2 VASc score.
exclude that some patients had asymptomatic
AFib recurrence.
Mean EF is normal. If a more representative
group of patients were enrolled it is hard to imag-
ine that EF would not be a predictor. Never-
theless, it would be reasonable to assume that
patients with lower EF would have also a propor-
tionate iLAV enlargement. This is consistent with
our previous published paper on a larger retro-
spective cohort which showed that EF was a pre-
dictor of AFib relapse at univariate analysis, but
not in the multivariable model.9
This is the first study to evaluate the re-
lationship between iLAV, CHA2DS2VASc score,
and AFib relapse after CV, showing intriguing
results.
Giving the number of the cohort, these top-
ics should be investigated in a larger prospec-
tive study, even if this work confirms the re-
sults of our retrospective one based on a larger
population.
TABLE IV
Multivariable Predictors of AFib Recurrence
Variable P OR CI
CHAD2S2VASc 0.51 0.96 0.16–5.74
Hypertension 0.65 0.96 0.16–5.73
ACE-i 0.32 2.74 0.39–19.94
N◦ of previous AFib Episodes 0.25 1.21 0.87–1.68
iLVmass (g/m2) 0.92 1.00 0.97–1.03
iLAV (mL/m2) 0.02 1.14 1.02–1.28
Values in bold are statistically significant P < 0.05.
ACE-i = indicates angiotensin converting enzyme inhibitors;
iLAV = indexed left atrial volume; iLV = indexed left ventricu-
lar; OR = odds ratio; CI = confidence interval.
Figure 2. Receiver-operator characteristic curves generated
to compare M-mode AP-LAd and iLAV as predictors of re-
currence of AFib after cardioversion. AFib = atrial fibrillation;
AUC = area under the curve; SE = standard error; CI = con-
fidence interval; AP-LAd = M-mode anteroposterior left atrial
diameter; iLAV = indexed left atrial volume.
Conclusions:
The present prospective study demonstrates that
iLAV is a significant and independent predictor of
AFib recurrence after successful CV, confirming
the results of our retrospective one. It is supe-
rior to M-mode AP-LAd because it allows a more
accurate assessment of the asymmetric remodel-
ing of the LA. Furthermore, iLAV is incremental to
clinical risk factors, and medical therapy in pre-
dicting AFib relapse, likely because LA remodel-
ing represents the final and macroscopic result of
the sum of each single predictor. Although lat-
est guidelines for AFib management13 mention
LA size assessment just in terms of M-mode AP
dimension, the present study encourages the use
of iLAV as a valuable tool for the clinician manag-
ing patients with AFib. Larger prospective stud-
ies are needed to establish iLAV utility in AFib
management.
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